Evolving lipid-based delivery systems in the management of neoplastic disease

Iuliana Shapira, Daniel R. Budman, Thomas Bradley, Richard J. Gralla

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Drug delivery systems for the therapeutic use of cytotoxic chemotherapy are an essential aspect of successful treatment and remain under active evaluation. Such systems offer advantages such as they can change the pharmacologic and pharmacodynamic properties of an active drug in preclinical screens to meet the needs of therapy in humans. For example, unstable or insoluble agents can be formulated in a manner to allow effective exposure in the tumor. Liposomal delivery systems are the most mature with regulatory approval for several liposomal preparations. The liposome is attractive as the charge, size, composition, and the payload (drug) can be manipulated to enhance efficacy. Targeting agents such as antibodies, antibody fragments, or ligands can be incorporated into the liposomal structure to enhance specificity. The liposome can be manipulated to be thermal or pH sensitive. In addition, variations of the liposome can incorporate more than one agent and also allow for sequential exposure of the active agents to the tumor. Additional lipid formulations include micelles and nanocochleates, which are earlier in development, but many offer an alternative to liposomal technology. The size, shape, adducts, and composition of the micelles may offer more flexibility in the delivery platform. Further clinical trials are eagerly awaited.

Original languageEnglish (US)
Pages (from-to)113-124
Number of pages12
JournalOncology Reviews
Volume3
Issue number2
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Disease Management
Liposomes
Micelles
Lipids
Immunoglobulin Fragments
Therapeutic Uses
Drug Delivery Systems
Pharmaceutical Preparations
Neoplasms
Hot Temperature
Clinical Trials
Ligands
Technology
Drug Therapy
Antibodies
Therapeutics

Keywords

  • Chemotherapy
  • Drug delivery
  • Liposomes
  • Nanoliposomes
  • Nanoparticles
  • Sphingosomes
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evolving lipid-based delivery systems in the management of neoplastic disease. / Shapira, Iuliana; Budman, Daniel R.; Bradley, Thomas; Gralla, Richard J.

In: Oncology Reviews, Vol. 3, No. 2, 06.2009, p. 113-124.

Research output: Contribution to journalArticle

Shapira, Iuliana ; Budman, Daniel R. ; Bradley, Thomas ; Gralla, Richard J. / Evolving lipid-based delivery systems in the management of neoplastic disease. In: Oncology Reviews. 2009 ; Vol. 3, No. 2. pp. 113-124.
@article{f99af7a7b7cd4d6dad515a6d266d6156,
title = "Evolving lipid-based delivery systems in the management of neoplastic disease",
abstract = "Drug delivery systems for the therapeutic use of cytotoxic chemotherapy are an essential aspect of successful treatment and remain under active evaluation. Such systems offer advantages such as they can change the pharmacologic and pharmacodynamic properties of an active drug in preclinical screens to meet the needs of therapy in humans. For example, unstable or insoluble agents can be formulated in a manner to allow effective exposure in the tumor. Liposomal delivery systems are the most mature with regulatory approval for several liposomal preparations. The liposome is attractive as the charge, size, composition, and the payload (drug) can be manipulated to enhance efficacy. Targeting agents such as antibodies, antibody fragments, or ligands can be incorporated into the liposomal structure to enhance specificity. The liposome can be manipulated to be thermal or pH sensitive. In addition, variations of the liposome can incorporate more than one agent and also allow for sequential exposure of the active agents to the tumor. Additional lipid formulations include micelles and nanocochleates, which are earlier in development, but many offer an alternative to liposomal technology. The size, shape, adducts, and composition of the micelles may offer more flexibility in the delivery platform. Further clinical trials are eagerly awaited.",
keywords = "Chemotherapy, Drug delivery, Liposomes, Nanoliposomes, Nanoparticles, Sphingosomes, Targeted therapy",
author = "Iuliana Shapira and Budman, {Daniel R.} and Thomas Bradley and Gralla, {Richard J.}",
year = "2009",
month = "6",
doi = "10.1007/s12156-009-0009-4",
language = "English (US)",
volume = "3",
pages = "113--124",
journal = "Oncology Reviews",
issn = "1970-5557",
publisher = "PagePress",
number = "2",

}

TY - JOUR

T1 - Evolving lipid-based delivery systems in the management of neoplastic disease

AU - Shapira, Iuliana

AU - Budman, Daniel R.

AU - Bradley, Thomas

AU - Gralla, Richard J.

PY - 2009/6

Y1 - 2009/6

N2 - Drug delivery systems for the therapeutic use of cytotoxic chemotherapy are an essential aspect of successful treatment and remain under active evaluation. Such systems offer advantages such as they can change the pharmacologic and pharmacodynamic properties of an active drug in preclinical screens to meet the needs of therapy in humans. For example, unstable or insoluble agents can be formulated in a manner to allow effective exposure in the tumor. Liposomal delivery systems are the most mature with regulatory approval for several liposomal preparations. The liposome is attractive as the charge, size, composition, and the payload (drug) can be manipulated to enhance efficacy. Targeting agents such as antibodies, antibody fragments, or ligands can be incorporated into the liposomal structure to enhance specificity. The liposome can be manipulated to be thermal or pH sensitive. In addition, variations of the liposome can incorporate more than one agent and also allow for sequential exposure of the active agents to the tumor. Additional lipid formulations include micelles and nanocochleates, which are earlier in development, but many offer an alternative to liposomal technology. The size, shape, adducts, and composition of the micelles may offer more flexibility in the delivery platform. Further clinical trials are eagerly awaited.

AB - Drug delivery systems for the therapeutic use of cytotoxic chemotherapy are an essential aspect of successful treatment and remain under active evaluation. Such systems offer advantages such as they can change the pharmacologic and pharmacodynamic properties of an active drug in preclinical screens to meet the needs of therapy in humans. For example, unstable or insoluble agents can be formulated in a manner to allow effective exposure in the tumor. Liposomal delivery systems are the most mature with regulatory approval for several liposomal preparations. The liposome is attractive as the charge, size, composition, and the payload (drug) can be manipulated to enhance efficacy. Targeting agents such as antibodies, antibody fragments, or ligands can be incorporated into the liposomal structure to enhance specificity. The liposome can be manipulated to be thermal or pH sensitive. In addition, variations of the liposome can incorporate more than one agent and also allow for sequential exposure of the active agents to the tumor. Additional lipid formulations include micelles and nanocochleates, which are earlier in development, but many offer an alternative to liposomal technology. The size, shape, adducts, and composition of the micelles may offer more flexibility in the delivery platform. Further clinical trials are eagerly awaited.

KW - Chemotherapy

KW - Drug delivery

KW - Liposomes

KW - Nanoliposomes

KW - Nanoparticles

KW - Sphingosomes

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=67650691925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650691925&partnerID=8YFLogxK

U2 - 10.1007/s12156-009-0009-4

DO - 10.1007/s12156-009-0009-4

M3 - Article

AN - SCOPUS:67650691925

VL - 3

SP - 113

EP - 124

JO - Oncology Reviews

JF - Oncology Reviews

SN - 1970-5557

IS - 2

ER -